A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Pomalidomide in Combination with Low-Dose Dexamethasone versus High-Dose Dexamethasone in Subjects with Refractory or Relapsed and Refractory Multiple Myeloma

Trial Profile

A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Pomalidomide in Combination with Low-Dose Dexamethasone versus High-Dose Dexamethasone in Subjects with Refractory or Relapsed and Refractory Multiple Myeloma

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Mar 2017

At a glance

  • Drugs Pomalidomide (Primary) ; Dexamethasone
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Acronyms NIMBUS
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 04 Dec 2016 Results published in an Acetylon Pharmaceuticals Media Release
    • 02 Nov 2016 Results of pooled analysis of individual patient data from this and other two trials (NCT00574288 and NCT01985126), presented at the 19th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
    • 07 Jun 2016 Pooled analysis results from this trial and other two trial (NCT00833833, NCT01712789) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top